Bioteque (4107) Q2 2024 earnings summary

Executive summary

• Revenue for Q2 2023 was NT$518.75 million, up 9.8% year-over-year; first half revenue reached NT$1,015.02 million, up 9.4% year-over-year.

• Net income for Q2 2023 was NT$124.52 million, up 21.4% year-over-year; first half net income was NT$250.21 million, up 24.3% year-over-year.

• Gross margin for Q2 2023 improved to 42% from 40% in Q2 2022.

Financial highlights

• Operating income for Q2 2023 was NT$151.56 million, up 18.8% year-over-year; first half operating income was NT$292.06 million, up 16.2% year-over-year.

• Basic EPS for Q2 2023 was NT$1.80, up from NT$1.48 in Q2 2022; first half basic EPS was NT$3.61, up from NT$2.90.

• Cash and cash equivalents as of June 30, 2023, were NT$1,537.66 million, up from NT$1,183.71 million a year earlier.

• Total assets as of June 30, 2023, were NT$4,839.62 million; equity attributable to owners was NT$3,155.39 million.

• Operating cash flow for the first half was NT$338.54 million, up from NT$218.16 million year-over-year.

Outlook and guidance

• Management expects no material impact from newly adopted or upcoming accounting standards.

• Operations are not affected by seasonality or cyclicality.